Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal is a research paper published in Brain (2022). On theSindex it has a DataRank of 0. It has been cited 92 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
CReATe Consortium
Grant: U01-NS107027
CReATe Consortium
Grant: R01-NS105479
NINDS NIH HHS
Grant: U01 NS107027
CReATe Consortium
Grant: U54-NS092091
NINDS NIH HHS
Grant: R01 NS105479
Motor Neurone Disease Association
Grant: TURNER/OCT18/989-797
NINDS NIH HHS
Grant: RF1 NS105479
NINDS NIH HHS
Grant: U54 NS092091
National Institutes of Health
Grant: 5R01NS105479-05
Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial
National Institutes of Health
Grant: 5U01NS107027-04
Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)
National Institutes of Health
Grant: 5U54NS092091-08
Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe)
U.S. National Institutes of Health
U.K. Motor Neurone Disease Association
FWCI
9.03
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial
Additional file 1 of A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial